Impact of Vaccination on Major Adverse Cardiovascular Events in Patients With COVID-19 Infection

N3C Consortium

doi:10.1016/j.jacc.2022.12.006

Impact of Vaccination on Major Adverse Cardiovascular Events in Patients With COVID-19 Infection

N3C Consortium

Research output: Contribution to journal › Letter › peer-review

48 Scopus citations

Original language	English
Pages (from-to)	928-930
Number of pages	3
Journal	Journal of the American College of Cardiology
Volume	81
Issue number	9
DOIs	https://doi.org/10.1016/j.jacc.2022.12.006
State	Published - 7 Mar 2023

Access to Document

10.1016/j.jacc.2022.12.006

Cite this

@article{e0e398feebae4e92a61eba1a3e05b3b6,

title = "Impact of Vaccination on Major Adverse Cardiovascular Events in Patients With COVID-19 Infection",

author = "\{N3C Consortium\} and Joy Jiang and Lili Chan and Justin Kauffman and Jagat Narula and Charney, \{Alexander W.\} and Wonsuk Oh and Girish Nadkarni",

note = "Funding Information: The analyses described in this publication were conducted with data or tools accessed through the NCATS N3C Data Enclave covid.cd2h.org/enclave and supported by CD2H - The National COVID Cohort Collaborative (N3C) IDeA CTR Collaboration 3U24TR002306-04S2 NCATS U24 TR002306. Dr Chan has consultancy agreements with Vifor Pharma, Inc; has received research funding from the National Institutes of Health; has received honoraria from Fresenius; and is supported in part by National Institute of Diabetes and Digestive and Kidney Diseases career development grant K23DK124645. Dr Oh is supported by NIDDK Institutional National Research Service award T32DK007757. Dr Nadkarni has consultancy agreements with AstraZeneca, BioVie, GLG Consulting, Pensieve Health, Reata, Renalytix, Siemens, and Variant Bio; has received research funding from Goldfinch Bio and Renalytix; has received honoraria from AstraZeneca, BioVie, Lexicon, and Reata; has patents or royalties with Renalytix; owns equity and stock options in Pensieve Health as a cofounder and Renalytix; has received financial compensation as a scientific board member and advisor to Renalytix; serves on the advisory board of Neurona Health; and serves in an advisory or leadership role for Pensieve Health and Renalytix. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. This research was possible because of the patients whose information is included within the data from participating organizations (covid.cd2h.org/dtas) and the organizations and scientists (covid.cd2h.org/duas) who have contributed to the on-going development of this community resource. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the N3C program. Funding Information: The analyses described in this publication were conducted with data or tools accessed through the NCATS N3C Data Enclave covid.cd2h.org/enclave and supported by CD2H - The National COVID Cohort Collaborative (N3C) IDeA CTR Collaboration 3U24TR002306-04S2 NCATS U24 TR002306. Dr Chan has consultancy agreements with Vifor Pharma, Inc; has received research funding from the National Institutes of Health; has received honoraria from Fresenius; and is supported in part by National Institute of Diabetes and Digestive and Kidney Diseases career development grant K23DK124645. Dr Oh is supported by NIDDK Institutional National Research Service award T32DK007757. Dr Nadkarni has consultancy agreements with AstraZeneca, BioVie, GLG Consulting, Pensieve Health, Reata, Renalytix, Siemens, and Variant Bio; has received research funding from Goldfinch Bio and Renalytix; has received honoraria from AstraZeneca, BioVie, Lexicon, and Reata; has patents or royalties with Renalytix; owns equity and stock options in Pensieve Health as a cofounder and Renalytix; has received financial compensation as a scientific board member and advisor to Renalytix; serves on the advisory board of Neurona Health; and serves in an advisory or leadership role for Pensieve Health and Renalytix. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. This research was possible because of the patients whose information is included within the data from participating organizations (covid.cd2h.org/dtas) and the organizations and scientists (covid.cd2h.org/duas) who have contributed to the on-going development of this community resource. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the N3C program. ",

year = "2023",

month = mar,

day = "7",

doi = "10.1016/j.jacc.2022.12.006",

language = "English",

volume = "81",

pages = "928--930",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier Inc.",

number = "9",

}

TY - JOUR

T1 - Impact of Vaccination on Major Adverse Cardiovascular Events in Patients With COVID-19 Infection

AU - N3C Consortium

AU - Jiang, Joy

AU - Chan, Lili

AU - Kauffman, Justin

AU - Narula, Jagat

AU - Charney, Alexander W.

AU - Oh, Wonsuk

AU - Nadkarni, Girish

N1 - Funding Information: The analyses described in this publication were conducted with data or tools accessed through the NCATS N3C Data Enclave covid.cd2h.org/enclave and supported by CD2H - The National COVID Cohort Collaborative (N3C) IDeA CTR Collaboration 3U24TR002306-04S2 NCATS U24 TR002306. Dr Chan has consultancy agreements with Vifor Pharma, Inc; has received research funding from the National Institutes of Health; has received honoraria from Fresenius; and is supported in part by National Institute of Diabetes and Digestive and Kidney Diseases career development grant K23DK124645. Dr Oh is supported by NIDDK Institutional National Research Service award T32DK007757. Dr Nadkarni has consultancy agreements with AstraZeneca, BioVie, GLG Consulting, Pensieve Health, Reata, Renalytix, Siemens, and Variant Bio; has received research funding from Goldfinch Bio and Renalytix; has received honoraria from AstraZeneca, BioVie, Lexicon, and Reata; has patents or royalties with Renalytix; owns equity and stock options in Pensieve Health as a cofounder and Renalytix; has received financial compensation as a scientific board member and advisor to Renalytix; serves on the advisory board of Neurona Health; and serves in an advisory or leadership role for Pensieve Health and Renalytix. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. This research was possible because of the patients whose information is included within the data from participating organizations (covid.cd2h.org/dtas) and the organizations and scientists (covid.cd2h.org/duas) who have contributed to the on-going development of this community resource. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the N3C program. Funding Information: The analyses described in this publication were conducted with data or tools accessed through the NCATS N3C Data Enclave covid.cd2h.org/enclave and supported by CD2H - The National COVID Cohort Collaborative (N3C) IDeA CTR Collaboration 3U24TR002306-04S2 NCATS U24 TR002306. Dr Chan has consultancy agreements with Vifor Pharma, Inc; has received research funding from the National Institutes of Health; has received honoraria from Fresenius; and is supported in part by National Institute of Diabetes and Digestive and Kidney Diseases career development grant K23DK124645. Dr Oh is supported by NIDDK Institutional National Research Service award T32DK007757. Dr Nadkarni has consultancy agreements with AstraZeneca, BioVie, GLG Consulting, Pensieve Health, Reata, Renalytix, Siemens, and Variant Bio; has received research funding from Goldfinch Bio and Renalytix; has received honoraria from AstraZeneca, BioVie, Lexicon, and Reata; has patents or royalties with Renalytix; owns equity and stock options in Pensieve Health as a cofounder and Renalytix; has received financial compensation as a scientific board member and advisor to Renalytix; serves on the advisory board of Neurona Health; and serves in an advisory or leadership role for Pensieve Health and Renalytix. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. This research was possible because of the patients whose information is included within the data from participating organizations (covid.cd2h.org/dtas) and the organizations and scientists (covid.cd2h.org/duas) who have contributed to the on-going development of this community resource. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the N3C program.

PY - 2023/3/7

Y1 - 2023/3/7

UR - https://www.scopus.com/pages/publications/85148339834

U2 - 10.1016/j.jacc.2022.12.006

DO - 10.1016/j.jacc.2022.12.006

M3 - Letter

AN - SCOPUS:85148339834

SN - 0735-1097

VL - 81

SP - 928

EP - 930

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 9

ER -